Stocks Health care WGS
NASDAQ · Health careGeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. brought in $460.8M of revenue over the twelve months to September 30, 2026, up 14.6% from a year earlier. It posted a net loss of $111M. Operating cash flow minus capital spending left $14.3M of free cash flow in fiscal 2025. At September 30, 2026 it held $96.1M in cash against $150M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about GeneDx Holdings Corp.
- Net worth
- GeneDx Holdings Corp. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $244.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $427.5M (+40.0% year on year), with a net loss of $21M. Over the 12 months to September 30, 2026: revenue $460.8M, net loss $111M.
- Cash flow
- In fiscal 2025 operations brought in $33.3M of cash; after $19M of capital spending, free cash flow was $14.3M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- GeneDx Holdings Corp.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What GeneDx Holdings Corp. does
GeneDx Holdings Corp. is registered with the SEC under industry code SIC 8000 (Services-Health Services). Its shares trade on NASDAQ under the ticker WGS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $427.5M | -$21M | -$0.73 | $14.3M |
| 2024 | $305.5M | -$52.3M | -$1.94 | -$34M |
| 2023 | $202.6M | -$175.8M | -$7.23 | -$185.4M |
| 2022 | $234.7M | -$549M | -$53.63 | -$326.3M |
| 2021 | $212.2M | -$245.4M | -$74.69 | -$199.8M |
| 2020 | $179.3M | -$241.3M | -$1,547,570.97 | -$117.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where WGS ranks in Health care
Latest SEC filings
What GeneDx Holdings Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5.4% to $123.1M versus the same quarter last year; diluted EPS -$0.41 versus -$0.27.
- November 9, 2026
- November 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $114.4M versus the same quarter last year; diluted EPS -$0.60 versus $0.36.
- August 3, 2026
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- July 21, 2026Delisting notice 25-NSE
- June 23, 2026
What is WGS worth? A DCF from its reported cash flow
Insider trades
What the people running GeneDx Holdings Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.8M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Fuchs ThomasDirector | Exercised options | 1,146 | - |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Exercised options | 18,750 | - |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Sold | 1,648 | $155.3K |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Sold | 148 | $14.1K |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Sold | 1,525 | $147.8K |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Sold | 4,141 | $406.9K |
| September 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | Sold | 3,039 | $300.8K |
| September 16, 2026 | Feeley KevinCHIEF FINANCIAL OFFICER | Exercised options | 7,197 | - |
Who owns WGS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Keith A. Meister13D, may seek influence with 8 related filers | 17.9% | May 22, 2026 |
| Eli Casdin13D, may seek influence with 9 related filers | 14.9% | May 31, 2024 |
| ARK Investment Management LLC13G, passive with 1 related filers | 5.33% | August 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 223 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Corvex Management LP | 4,784,570 | +1,556,421 |
| Casdin Capital, LLC | 3,707,164 | +700,000 |
| BlackRock, Inc. | 1,706,239 | +155,531 |
| Goldman Sachs Group Inc | 1,669,441 | +334,461 |
| ARK Investment Management LLC | 1,610,189 | +285,606 |
| William Blair Investment Management, LLC | 1,400,653 | +625,384 |
| Morgan Stanley | 988,297 | +456,062 |
| Vanguard Capital Management LLC | 879,003 | +20,420 |
| Citadel Advisors LLC | 865,462 | +218,061 |
| First Light Asset Management, LLC | 783,923 | +540,996 |
| Deep Track Capital, LP | 700,000 | new |
| Sumitomo Mitsui Trust Group, Inc. | 666,581 | +33,124 |
| Amova Asset Management Americas, Inc. | 666,581 | +27,781 |
| Assenagon Asset Management S.A. | 606,866 | +511,738 |
| Zweig-DiMenna Associates LLC | 571,950 | -117,340 |
| Geode Capital Management, LLC | 552,125 | +2,978 |
| State Street Corp | 527,815 | +55,370 |
| Gagnon Securities LLC | 524,865 | +221,716 |
| Aberdeen Group plc | 457,201 | +227,105 |
| Wellington Management Group Llp | 347,927 | +6,922 |
Insiders
10 insiders reported holding 8,939,895 shares in total, about $490.2M at the last price.
| Holder | Shares |
|---|---|
| Meister Keith A.Director, 10% owner | 4,808,2754,784,570 held indirectly |
| Casdin Capital, LLCDirector, 10% owner | 3,707,1643,707,164 held indirectly |
| Ruch JoshuaDirector | 153,382120,083 held indirectly |
| Stueland KatherineCHIEF EXECUTIVE OFFICER, Director | 115,476 |
| Pfenniger Richard C JrDirector | 45,082 |
| Feeley KevinCHIEF FINANCIAL OFFICER | 44,945 |
| Leproust Emily M.Director | 24,852 |
| Casdin EliDirector, 10% owner | 24,093 |
| Ryan JasonDirector | 15,480 |
| Fuchs ThomasDirector | 1,146 |
Questions about WGS
What does GeneDx Holdings Corp. do?
GeneDx Holdings Corp. is a company in the Health care sector, listed on NASDAQ as WGS. Its shares trade on NASDAQ under the ticker WGS.
What is GeneDx Holdings Corp.'s net worth?
GeneDx Holdings Corp. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $244.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is GeneDx Holdings Corp. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $111M on revenue of $460.8M.
How much revenue does GeneDx Holdings Corp. make?
Over the twelve months to September 30, 2026 GeneDx Holdings Corp. reported revenue of $460.8M. That is 14.6% more than a year earlier.
When did GeneDx Holdings Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is GeneDx Holdings Corp.'s next earnings report?
GeneDx Holdings Corp.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare WGS with
Follow WGS
Get an email when GeneDx Holdings Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values GeneDx Holdings Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.